Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Camurus AB ( (SE:CAMX) ).
Camurus has appointed Anders Vadsholt as its new Chief Financial Officer, effective July 1, 2025. Vadsholt brings significant financial and M&A experience from the biotech and pharmaceutical sectors, having previously served as CFO for Orphazyme A/S and Topotarget A/S. This strategic appointment is expected to support Camurus’ continued growth and diversification, enhancing its position in the biopharmaceutical industry. The transition is set to be smooth, with outgoing CFO Jon Garay Alonso remaining until August to facilitate the change.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international, science-led biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines for patients with severe and chronic diseases. Utilizing its proprietary FluidCrystal technology and extensive R&D expertise, Camurus has a pipeline that includes treatments for dependence, pain, cancer, and endocrine diseases. The company operates across Europe, the US, and Australia, with headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 74,925
Current Market Cap: SEK37.12B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.